Publication date: Apr 11, 2019
This post was originally published on this site The U. S. Food and Drug Administration (FDA) has given fast track designation to AMT-130, uniQure’s gene therapy candidate for the treatment of Huntington’s disease. -We are nearing the initiation of a Phase I/II study of AMT-130, the first one-time administered AAV gene therapy to enter clinical testing for Huntington’s disease, and are on track to treat the first patient in the second half of 2019,” Kapusta said. AMT-130 is an experimental gene therapy designed to block production of the mutated form of the huntingtin (HTT) protein, the underlying cause of Huntington’s disease. The post FDA Places Gene Therapy AMT-130 on Fast Track to Speed Development appeared first on Huntington’s Disease News.
- uniQure Receives FDA Fast Track Designation for AMT-130 Gene Therapy for the Treatment of Huntington’s Disease
- Biomarker Platform That May Track Huntington’s Decades Before Symptom Onset Receives FDA Letter of Support
- Genistein Promotes Clearance of Mutant Huntington’s Disease Protein, Study Shows
- An Updated Trial Design for Roche’s Huntingtin Lowering Trial